EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood–Brain Barrier

Tobias Gustavsson, Thomas Kustermann, Lars Hvass iD, Thomas E Wuensche, Anne Skovsbo Clausen, Sophie Stotz iD, Vladimir Shalgunov iD, Sara Lopes van den Broek, Gitte M Knudsen, Blanca Aldana, Elena Ferri iD, Giuseppe Cannazza iD und 6 weitere

Molecular Pharmaceutics · 01.12.2025 · 22 (12) · 7600-7610

DOI: 10.1021/acs.molpharmaceut.5c01180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 06.11.2025. Verfasst von Tobias Gustavsson und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, …. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Positron-Emission Tomography, Antibodies, Monoclonal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kr?ftens Bek?mpelse, Danmarks Frie Forskningsfond, Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pretargeted PET imaging offers a powerful approach to improve nuclear imaging contrast and reduce systemic radiation exposure, yet its application in the brain has been limited by the blood-brain barrier (BBB). Here, we demonstrate, for the first time, successful pretargeted PET imaging of a brain target enabled by a bispecific antibody engineered for transferrin receptor-mediated BBB transcytosis. By combining this brain shuttle with a novel 18F-labeled tetrazine, we achieve specific, quantifiable detection of brain-localized Aβ aggregates, validated through PET imaging and histological analysis. This proof-of-concept establishes a versatile, noninvasive imaging platform with broad potential for assessing biologic drug candidates and CNS targets previously considered intractable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood-Brain BarrierPositron-Emission TomographyAntibodies, MonoclonalAnimalsReceptors, TransferrinMiceBrainHumansFluorine RadioisotopesTranscytosisAntibodies, BispecificRadiopharmaceuticals

Stichwörter der Autor:innen

Imaging CNSblood−brain barrierpretargetingtetrazine ligationtransferrin receptor

Substanzen

Receptors, TransferrinAntibodies, MonoclonalFluorine RadioisotopesAntibodies, BispecificRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
  • Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland.
  • Cluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, 2100 Copenhagen Ø, Denmark.
  • Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
  • Neurobiology Research Unit and Institute for Clinical Medicine, Copenhagen University Hospital Rigshospitalet and University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
  • Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125 Modena, Italy.

ORCID-Profile: Lars Hvass, Sophie Stotz, Vladimir Shalgunov, Elena Ferri, Giuseppe Cannazza, Luca Gobbi, Umberto Maria Battisti, Andreas Kjaer, Matthias M Herth

Förderung

  • Kr?ftens Bek?mpelse
  • Danmarks Frie Forskningsfond
  • Novo Nordisk Fonden
  • HORIZON EUROPE Marie Sklodowska-Curie Actions
  • Horizon 2020 Framework Programme
  • Innovationsfonden
  • Lundbeck Foundation
  • Research Foundation of Rigshospitalet

Zitieren

APA

Gustavsson, T., Kustermann, T., Hvass, L., Wuensche, T. E., Clausen, A. S., Stotz, S., Shalgunov, V., Lopes van den Broek, S., Knudsen, G. M., Aldana, B., Ferri, E., Cannazza, G., Niewoehner, J., Gobbi, L., Honer, M., Battisti, U. M., Kjaer, A., & Herth, M. M. (2025). Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood–Brain Barrier. Molecular Pharmaceutics, 22(12), 7600-7610. https://doi.org/10.1021/acs.molpharmaceut.5c01180

Vancouver

Gustavsson T, Kustermann T, Hvass L, Wuensche TE, Clausen AS, Stotz S, et al. Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood–Brain Barrier. Molecular Pharmaceutics. 2025;22(12):7600-7610. doi:10.1021/acs.molpharmaceut.5c01180

BibTeX
@article{Gustavsson2025,
  author = {Gustavsson, Tobias and Kustermann, Thomas and Hvass, Lars and Wuensche, Thomas E and Clausen, Anne Skovsbo and Stotz, Sophie and Shalgunov, Vladimir and Lopes van den Broek, Sara and Knudsen, Gitte M and Aldana, Blanca and Ferri, Elena and Cannazza, Giuseppe and Niewoehner, Jens and Gobbi, Luca and Honer, Michael and Battisti, Umberto Maria and Kjaer, Andreas and Herth, Matthias M},
  title = {Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood–Brain Barrier},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  volume = {22},
  number = {12},
  pages = {7600--7610},
  doi = {10.1021/acs.molpharmaceut.5c01180}
}
Kostenlos starten →